Back to Search
Start Over
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium.
- Source :
-
Current opinion in molecular therapeutics [Curr Opin Mol Ther] 2002 Dec; Vol. 4 (6), pp. 606-13. - Publication Year :
- 2002
-
Abstract
- MLN-591 is a monoclonal antibody specific for prostate-specific membrane antigen that is being developed by Cornell University, BZL Biologics, ImmunoGen Inc and Millennium Pharmaceuticals Inc for the potential treatment of prostate cancer. MLN-591 was in phase II trials by May 2002.
- Subjects :
- Animals
Carboxypeptidases antagonists & inhibitors
Carboxypeptidases immunology
Clinical Trials as Topic statistics & numerical data
Drug Delivery Systems methods
Drug Evaluation legislation & jurisprudence
Drug Evaluation methods
Glutamate Carboxypeptidase II
Humans
Male
Technology, Pharmaceutical legislation & jurisprudence
Antigens, Surface
Carboxypeptidases metabolism
Technology, Pharmaceutical methods
Subjects
Details
- Language :
- English
- ISSN :
- 1464-8431
- Volume :
- 4
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Current opinion in molecular therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 12596364